GE Healthcare says recovery in supply of contrast media is on the way

GE Healthcare says its contrast media products are used in more than 100 million procedures globally every year. [Image courtesy of GE Healthcare]

GE Healthcare (NYSE:GE) announced today that it is on the way toward restabilizing its global supply of iodinated contrast media — a vital imaging agent.

The company said its Shanghai facility, previously closed amid COVID-19 restrictions in China, will be close to 100% production capacity by next week. Said GE: “We will continue to work with impacted customers to help them plan several weeks ahead as supply progressively recovers.”

According to a recent New York Times report, thousands of Americans have had to wait for exams because of the shortage. As related by NYT, FDA Commissioner Dr. Robert Califf described the situation as “just unbelievable” while testifying to a U.S. Senate committee. “Someone with a stroke or heart attack wouldn’t b…

Read more
  • 0

GE Healthcare says recovery in supply of contrast media is on the way

GE Healthcare says its contrast media products are used in more than 100 million procedures globally every year. [Image courtesy of GE Healthcare]GE Healthcare (NYSE:GE) announced today that it is on the way toward restabilizing its global supply of iodinated contrast media — a vital imaging agent.

The company said its Shanghai facility, previously closed amid COVID-19 restrictions in China, will be close to 100% production capacity by next week. Said GE: “We will continue to work with impacted customers to help them plan several weeks ahead as supply progressively recovers.”

According to a recent New York Times report, thousands of Americans have had to wait for exams because of the shortage. As related by NYT, FDA Commissioner Dr. Robert Califf described the situation as “just unbelievable” while testifying to a U.S. Senate committee. “Someone with a stroke or heart attack wouldn’t be able to get an angiogram.”

The closure of the Shangha…

Read more
  • 0

Schott expands Chinese glass tubing plant

Schott’s pharmaceutical glass tubing site in Jinyun, China [Image courtesy of Schott]

Schott recently announced that it has completed the next expansion stage at its pharmaceutical glass tubing site in Jinyun, China.

The company completed construction at the site in just 15 months despite the COVID-19 pandemic, with production starting in November 2020. The plant is meant to create a solid production base for high-quality borosilicate glass tubing in the local Chinese market. The tubing is for pharma containers that store vaccines (e.g., against COVID-19) and other drugs.

“Right on schedule with our planning, we have doubled our melting capacity. It’s another big milestone for pharma tubing in China. The expanded infrastructure will enable a reliable local supply of glass tubing, which is needed urgently to serve the increased demand for pharmaceutical packaging,” Patrick Marksc…

Read more
  • 0

China rebuffs WHO’s plan to continue investigating origins of COVID-19

The possibility that SARS-CoV-2 resulted from a laboratory accident has gained a degree of plausibility among several world leaders.

But China has rejected calls for further investigation into the matter, saying such allegations disregard “common sense,” as Zeng Yixin, vice-minister of the National Health Commission (NHC), said at a press briefing.

White House press secretary Jen Psaki criticized China’s stance, adding in a press briefing that “their position is irresponsible and, frankly, dangerous.”

China has also entertained a theory that Fort Detrick, an Army base in Maryland, is the source of the pandemic.

While the Fort Detrick lab researches infectious viruses, there is no evidence it is the outbreak’s source.

After initially discounting the possibility of the lab-leak scenario, the WHO has recommended further studies in China. Recently, the organization sought to audit laboratories and markets in Wuhan.

The investigation into…

Read more
  • 0

Report: China begins testing COVID-19 nasal spray vaccine

[Photo by Fusion Medical Animation on Unsplash]

China has reportedly begun human testing for a COVID-19 vaccine which utilizes nasal spray instead of an injection.

A report in Bloomberg cites a registration in the Chinese Clinical Trial Registry confirming that the nasal spray vaccine candidate developed by Xiamen University, Hong Kong University and Beijing Wantai Biological Pharmacy Enterprise is undergoing Phase I human testing.

Nasal spray vaccines have been developed for influenza and are often used for children and adults who seek alternatives to a needle injection and in this case would add another method for administering the much sought-after COVID-19 vaccine.

Bloomberg said the vaccine candidate is the 10th from China to reach the human testing phase. An NPR report also said some scientists have expressed hope that a vaccine sprayed in the nose would be better suited to stopping the sprea…

Read more
  • 0

Hackers targeted pharma and other IP for Chinese government, indictment claims

A federal grand jury in Spokane, Wash. has indicted two Chinese nationals on charges that they hacked into pharma companies and hundreds of other businesses, governments and organizations — in some cases on behalf of the Chinese Ministry of State Security.

The 11-count indictment, which the U.S. Department of Justice announced today, alleges that Li Xiaoyu and Dong Jiazhi for the past 10 years targeted companies in countries with high technology industries, including the United States. They stole terabytes of data.

“China has now taken its place, alongside Russia, Iran and North Korea, in that shameful club of nations that provide a safe haven for cybercriminals in exchange for those criminals being ‘on-call’ to work for the benefit of the state, here to feed the Chinese Communist party’s insatiable hunger for American and other non-Chinese companies’ hard-earned intellectual property, including COVID-19 research,” Assistant Attorney General for National Securi…

Read more
  • 0

Hackers targeted medtech and other IP for Chinese government, indictment claims

A federal grand jury in Spokane, Wash. has indicted two Chinese nationals on charges that they hacked into medtech companies and hundreds of other businesses, governments and organizations — in some cases on behalf of the Chinese Ministry of State Security.

The 11-count indictment, which the U.S. Department of Justice announced today, alleges that Li Xiaoyu and Dong Jiazhi for the past 10 years targeted companies in countries with high technology industries, including the United States. They stole terabytes of data.

“China has now taken its place, alongside Russia, Iran and North Korea, in that shameful club of nations that provide a safe haven for cybercriminals in exchange for those criminals being ‘on-call’ to work for the benefit of the state, here to feed the Chinese Communist party’s insatiable hunger for American and other non-Chinese companies’ hard-earned intellectual property, including COVID-19 research,” Assistant Attorney General for National Secur…

Read more
  • 0

Edwards Lifesciences wins approval in China for Sapien 3

Edwards Lifesciences’ Sapien 3 Ultra TAVR [Image courtesy of Edwards Lifesciences]

Edwards Lifesciences (NYSE:EW) announced today that it received regulatory approval in China for its Sapien 3 transcatheter heart valve.

Sapien 3 TAVR (transcatheter aortic valve replacement) is used in the treatment of patients suffering from severe, symptomatic aortic stenosis (AS) who are at high risk for or unable to undergo open-heart surgery.

According to a news release, the Sapien 3 TAVR valves are the most widely studied transcatheter valves, treating more than 30,000 patients in clinical trials across 65 different countries. The China Sapien 3 study supported the regulatory approval, having provided positive real-world results alongside three randomized controlled “Partner” studies.

Edwards offers the valve in 20mm, 23mm, 26mm and 29mm sizes for high-risk patients in China. The Irvine, Calif.-bas…

Read more
  • 0